


PRODUCT INFORMATION

4-Methoxyamphetamine (hydrochloride) (exempt preparation)

Item No. 15691

CAS Registry No.: 3706-26-1
Formal Name: 4-methoxy- α -methyl-benzeneethanamine, monohydrochloride
Synonyms: 4-MA, *p*-MA, *para*-Methoxyamphetamine, PMA
MF: C₁₀H₁₅NO • HCl
FW: 201.7
Purity: ≥98%
UV/Vis.: λ_{max} : 225, 277, 283 nm
Supplied as: A 1 mg/ml solution in methanol
Storage: -20°C
Stability: ≥5 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

4-MA (hydrochloride) (exempt preparation) is supplied as a solution in methanol. To change the solvent, simply evaporate the methanol under a gentle stream of nitrogen and immediately add the solvent of choice. Solvents such as ethanol, DMSO, and dimethyl formamide purged with an inert gas can be used. The solubility of 4-MA (hydrochloride) (exempt preparation) in these solvents is approximately 30 mg/ml.

Further dilutions of the stock solution into aqueous buffers or isotonic saline should be made prior to performing biological experiments. Ensure that the residual amount of organic solvent is insignificant, since organic solvents may have physiological effects at low concentrations. If an organic solvent-free solution of 4-MA (hydrochloride) (exempt preparation) is needed, it can be prepared by evaporating the methanol and directly dissolving the neat oil in aqueous buffers. The solubility of 4-MA (hydrochloride) (exempt preparation) in PBS (pH 7.2) is approximately 10 mg/ml. We do not recommend storing the aqueous solution for more than one day.

Description

4-MA is a serotonergic drug of the amphetamine class.¹ 4-MA exhibits both structural and pharmacological similarity to 3,4-methylenedioxymethamphetamine and may be a more potent hallucinogen, particularly through its effects on serotonergic transmission and through reversible inhibition of the enzyme MAO-A.¹⁻⁴ This product is intended for research and forensic applications.

References

1. Staack, R.F. and Maurer, H.H. Metabolism of designer drugs of abuse. *Curr. Drug Metab.* **6**(3), 259-274 (2005).
2. Kraner, J.C., McCoy, D.J., Evans, M.A., et al. Fatalities caused by the MDMA-related drug paramethoxyamphetamine (4-MA). *J. Anal. Toxicol.* **25**(7), 645-648 (2001).
3. Martin-Iverson, M.T., Yamada, N., By, A.W., et al. "Designer" amphetamines: Effects on behavior and monoamines with or without reserpine and/or α -methyl-*para*-tyrosine pretreatment. *J. Psychiatr. Neurosci.* **16**(5), 253-261 (1991).
4. Tseng, L.-F. 5-hydroxytryptamine uptake inhibitors block *para*-methoxyamphetamine-induced 5-HT release. *Br. J. Pharmacol.* **66**(2), 185-190 (1979).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 06/26/2026

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 • USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM